martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

7 Signs Your 401(k) Is Quietly Underperforming

View original at finance.yahoo.com
7 Signs Your 401(k) Is Quietly Underperforming Quick Read iShares Core S&P 500 ETF (IVV) charges an expense ratio of 0.03%, the benchmark for low-cost index investing, while many 401(k) plans offer index-style funds charging over 0.5%—a gap that compounds into six-figure losses on a $500,000 balance over 20 years…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Target-date funds from high-fee providers charge 0.6% to 0.8% annually compared to under 0.15% for low-cost alternatives

    60% confidence
  • Most 401(k) account holders unknowingly lose wealth through structural problems like excessive fees, concentrated employer stock positions above 10%, drift from target allocations, and failure to rebalance—costing participants tens of thousands in foregone compounding

    60% confidence
  • A $100,000 investment at a 7% gross annual return can grow substantially over 20 years at near-zero fees, while a 1% expense ratio meaningfully reduces that outcome

    60% confidence
  • Staying in a low-yielding default option while equity markets compound is one of the most expensive passive decisions a retirement saver can make

    60% confidence
  • Actively managed funds charge more and, over long periods, most underperform their benchmark indexes after fees

    60% confidence
  • Many 401(k) plans offer index-style funds charging over 0.5%, a gap that compounds into six-figure losses on a $500,000 balance over 20 years compared to iShares Core S&P 500 ETF's 0.03% expense ratio

    60% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · federal funds rate3.75 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com